Author: Black Diamond Therapeutics, Inc

Posted Date:

April 21, 2026

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

Black Diamond Therapeutics, Inc

April 21, 2026
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Black Diamond Therapeutics, Inc

March 16, 2026
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Black Diamond Therapeutics, Inc

March 2, 2026